Drug intelligence / Profile preview

DWP DT-2501

Development stage: Unknown
Lead developer: Daewoo Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWP DT-2501 is an investigational pharmaceutical candidate developed by Daewoo Pharma for the treatment of hyperlipidemia. As of 2024, the project is in Phase 1 clinical trials. While the specific pharmacological profile and molecular targets have not been publicly detailed, the candidate is part of Daewoo's research and development pipeline focusing on metabolic disorders. The 'DT' prefix in the company's nomenclature typically designates internally developed formulations or incrementally modified drugs (IMDs) within their R&D structure.

Beyond the preview

Go deeper on DWP DT-2501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWP DT-2501.

Explore the full profile